145 related articles for article (PubMed ID: 23475578)
1. Predictive and prognostic values of Tau and BubR1 protein in prostate cancer and their relationship to the Gleason score.
Cirak Y; Sarsik B; Cakar B; Sen S; Simsir A; Uslu R
Med Oncol; 2013 Jun; 30(2):526. PubMed ID: 23475578
[TBL] [Abstract][Full Text] [Related]
2. Predictive and prognostic values of BubR1 and synuclein-gamma expression in breast cancer.
Cirak Y; Furuncuoglu Y; Yapicier O; Alici S; Argon A
Int J Clin Exp Pathol; 2015; 8(5):5345-53. PubMed ID: 26191236
[TBL] [Abstract][Full Text] [Related]
3. Predictive and Prognostic Role of Lipocalin-2 Expression in Prostate Cancer and Its Association with Gleason Score.
Ulusoy MH; Cirak Y; Adali Y
Prostate Cancer; 2021; 2021():8836043. PubMed ID: 33542838
[TBL] [Abstract][Full Text] [Related]
4. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.
Baquero MT; Lostritto K; Gustavson MD; Bassi KA; Appia F; Camp RL; Molinaro AM; Harris LN; Rimm DL
Breast Cancer Res; 2011 Nov; 13(5):R85. PubMed ID: 21888627
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer.
Kushnir I; Mallick R; Ong M; Canil C; Bossé D; Koczka K; Reaume NM
Cancer Chemother Pharmacol; 2020 May; 85(5):863-868. PubMed ID: 32240336
[TBL] [Abstract][Full Text] [Related]
7. PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study.
Kim SH; Park WS; Park BR; Joo J; Joung JY; Seo HK; Chung J; Lee KH
Asian J Androl; 2017; 19(4):458-462. PubMed ID: 27232854
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
Lara PN; Chee KG; Longmate J; Ruel C; Meyers FJ; Gray CR; Edwards RG; Gumerlock PH; Twardowski P; Doroshow JH; Gandara DR
Cancer; 2004 May; 100(10):2125-31. PubMed ID: 15139054
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
[TBL] [Abstract][Full Text] [Related]
11. Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death.
Mortezavi A; Salemi S; Rupp NJ; Rüschoff JH; Hermanns T; Poyet C; Randazzo M; Simon HU; Moch H; Sulser T; Wild P; Eberli D
Oncotarget; 2017 May; 8(19):31765-31774. PubMed ID: 28423666
[TBL] [Abstract][Full Text] [Related]
12. Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness.
Wissing MD; De Morrée ES; Dezentjé VO; Buijs JT; De Krijger RR; Smit VT; Van Weerden WM; Gelderblom H; van der Pluijm G
Oncotarget; 2014 Sep; 5(17):7357-67. PubMed ID: 25277178
[TBL] [Abstract][Full Text] [Related]
13. The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence.
Zhang C; Kallakury BV; Ross JS; Mewani RR; Sheehan CE; Sakabe I; Luta G; Kumar D; Yadavalli S; Starr J; Sreenath TL; Srivastava S; Pollard HB; Eidelman O; Srivastava M; Kasid UN
Int J Cancer; 2013 Jul; 133(1):31-42. PubMed ID: 23280553
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.
Magi-Galluzzi C; Zhou M; Reuther AM; Dreicer R; Klein EA
Cancer; 2007 Sep; 110(6):1248-54. PubMed ID: 17674353
[TBL] [Abstract][Full Text] [Related]
15. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.
Ploussard G; Terry S; Maillé P; Allory Y; Sirab N; Kheuang L; Soyeux P; Nicolaiew N; Coppolani E; Paule B; Salomon L; Culine S; Buttyan R; Vacherot F; de la Taille A
Cancer Res; 2010 Nov; 70(22):9253-64. PubMed ID: 21045157
[TBL] [Abstract][Full Text] [Related]
16. The Proteome of Primary Prostate Cancer.
Iglesias-Gato D; Wikström P; Tyanova S; Lavallee C; Thysell E; Carlsson J; Hägglöf C; Cox J; Andrén O; Stattin P; Egevad L; Widmark A; Bjartell A; Collins CC; Bergh A; Geiger T; Mann M; Flores-Morales A
Eur Urol; 2016 May; 69(5):942-52. PubMed ID: 26651926
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of biological profiles of benign prostate hyperplasia and prostate cancer as potential diagnostic, prognostic and predictive indicators.
Makarewicz R; Zyromska A; Andrusewicz H
Folia Histochem Cytobiol; 2011; 49(3):452-7. PubMed ID: 22038225
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
[TBL] [Abstract][Full Text] [Related]
20. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
